Minami Keita, Narimatsu Rei, Sasaki Hajime, Tanabe Tatsu, Tanaka Hiroshi
Department of Kidney Transplant Surgery and Urology Sapporo City General Hospital Sapporo Hokkaido Japan.
IJU Case Rep. 2025 Apr 8;8(3):257-260. doi: 10.1002/iju5.70019. eCollection 2025 May.
We report a case in which enfortumab vedotin (EV) therapy was administered as a third-line treatment for locally advanced bladder cancer (bc), enabling successful radical resection.
This report describes the case of a 69-year-old male patient with locally advanced bc and pelvic lymph node (LN) metastases. After the failure of first-line chemotherapy and second-line immunotherapy, the patient received EV as third-line treatment. EV therapy resulted in significant tumor reduction, enabling successful radical cystectomy and lymph node dissection (LND). The patient remained recurrence-free for 22 months post-surgery.
EV therapy suggests that it is a promising avenue for further exploration, potentially redefining the therapeutic landscape of historically challenging cases.
我们报告了一例将恩杂鲁胺（EV）疗法作为局部晚期膀胱癌（BC）的三线治疗方案，从而实现成功根治性切除的病例。
本报告描述了一名69岁男性患者，患有局部晚期BC并伴有盆腔淋巴结（LN）转移。一线化疗和二线免疫治疗失败后，该患者接受EV作为三线治疗。EV疗法使肿瘤显著缩小，从而成功进行根治性膀胱切除术和淋巴结清扫术（LND）。患者术后22个月无复发。
EV疗法表明这是一个有前景的进一步探索途径，可能重新定义以往具有挑战性病例的治疗格局。
